Henry Ford Health

Henry Ford Health Scholarly Commons
Pharmacy Articles

Pharmacy

7-6-2022

Evaluating the Impact of Substance Use Disorder Resources on
Outcomes of Persons Who Inject Drugs with Infections
Sage B. Greenlee
Rachel M. Kenney
Charles T. Makowski
Elizabeth Bulat
Indira Brar

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/pharmacy_articles

Authors
Sage B. Greenlee, Rachel M. Kenney, Charles T. Makowski, Elizabeth Bulat, Indira Brar, and Susan L. Davis

BRIEF REPORT

Evaluating the Impact of Substance Use Disorder Resources
on Outcomes of Persons Who Inject Drugs with Infections
Sage B. Greenlee, PharmD, Rachel M. Kenney, PharmD, Charles T. Makowski, PharmD,
Elizabeth Bulat, MD, Indira Brar, MD, and Susan L. Davis, PharmD
Objective: The aim of the study is to evaluate the impact of inpatient
substance use disorder (SUD) resources on outcomes of persons who
inject stimulants and/or opioids (PWIDs) with infections.
Methods: This retrospective cohort evaluated PWIDs hospitalized
from July 1, 2020, to May 31, 2021, and prescribed an antimicrobial
course. The patients were compared based on inpatient implementation
of SUD resources, including consultation of addiction medicine/
behavioral health, implementation of an opioid withdrawal treatment
protocol, or continuation/initiation of medications for opioid use disorder. The primary outcome was a composite of antibiotic completion, no
unplanned discharge, and no 30-day readmission. Notable secondary
outcomes included length of stay and presence of stigmatizing language in the electronic medical record.
Results: A total of 119 patients were analyzed—74 (62.2%) received
SUD resources. The primary outcome was met by 43 patients with
SUD resources implemented (58.1%) and 19 patients without resources
(42.2%, P = 0.093). After adjustment for infection type, implementation of SUD resources (adjusted odds ratio, 2.593; 95% confidence interval, 1.162–5.789) was independently associated with primary outcome success. The patients who received SUD resources had a median
length of stay of 7 days (4–13.3) compared with 4 days (2–6.5) in those
without resources ( P < 0.001). Stigmatizing language was present in
98% of patient electronic medical records.
Conclusions: Patient care provided to PWIDs with infections is optimized when SUD resources are implemented. This study further supports the necessity of improving SUD management when PWIDs are
admitted to healthcare facilities.
Key Words: persons who inject drugs, substance use disorder
resources, unplanned discharge
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ubstance use disorder (SUD) is described as “a mental disorder that affects a person’s brain and behavior, leading to a
person’s inability to control their use of substances.”1 The opioid
epidemic contributes significantly to SUD development, and
stimulant overuse is rising.2–4 Each substance use route has
advantages/disadvantages. Injection use provides rapid onset
yet high risk of injuries and infection.5 In addition, healthcare
barriers are evident for persons who inject drugs (PWIDs), with
inpatient withdrawal management and SUD resource implementation being missed opportunities and up to 30% of admissions having unplanned discharges.6–8 Literature demonstrates
improved outcomes and decreased unplanned discharges in persons with opioid use disorder (OUD) when addiction medicine
is consulted and/or when medications for OUD (MOUDs) are
used.9,10 This study seeks to expand upon literature by evaluating the impact of SUD resources on PWIDs, including both
stimulants and opioids, admitted with infections.

S

METHODS
This institutional review board–approved (IRB #14361),
retrospective cohort was conducted across a 5-hospital
healthcare system in Southeast Michigan. Persons who inject
drugs, 18 years or older, admitted July 1, 2020, to May 31,
2021, for an infection were included if prescribed antimicrobials
72 hours or more. Exclusion criteria included comfort care,
withdrawal of care, or transfer to an outside hospital.
Patients were identified using International Classification of
Diseases, Tenth Revision (ICD-10) codes F11–16 and F18–19.
Chart review confirmed individuals were PWIDs by using terms:
intravenous drug use (IVDU)/intravenous drug abuse (IVDA),
intravenous (IV) heroin/methamphetamine/cocaine/drug, and
injection drug. Data collection was standardized on an electronic case report form using the electronic medical record
(EMR). The cohort was divided based on inpatient SUD resource implementation. Substance use disorder resources were
defined as consultation of addiction medicine/behavioral health,
implementation of an opioid withdrawal treatment protocol, or
continuation or initiation of MOUDs (buprenorphine or methadone). The primary outcome was a composite of antimicrobial
course completion, inpatient stay without an unplanned discharge, and no 30-day readmission. Secondary outcomes included individual composite measures, length of stay, mortality,
adverse events, and presence of stigmatizing language in EMR.11
Organism isolated, infection type, and discharge SUD resources
were evaluated. Extensive patient characteristics were also collected. Discharge SUD resources were defined as prescribing
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of naloxone/buprenorphine, scheduling/attendance of a behavioral health follow-up visit, or inpatient treatment facility
admission.
Categorical variables were analyzed using χ2. Continuous variables having nonparametric distribution were analyzed
using Mann-Whitney U. A multivariable regression analysis

was performed to assess variables associated with the primary
outcome, using an n:K ratio of 10:1, variables with a P value
less than 0.2 and clinical relevance. Odds ratios (ORs) and confidence intervals (95% CIs) were used to report data. Using a
2-sided ⍺ = 0.05 and a β = 0.2 (80%), a sample size of 122
was calculated to detect 30% improvement.7 P values less than

TABLE 1. Baseline Characteristics and Bivariate Outcome Analysis
Variable, n (%), Median (IQR)
Age, yr
Sex, male
Gender
Male
Transgender
Race
Black
White
Other
BMI
CCI
HIV
HCV
Language, English
Sexual orientation
Straight
Do not know
Chose not to disclose
Gay/lesbian
Not documented
Education level
Middle school
High school/GED
Some college
College
Postcollege
Not documented
Insurance coverage
Insurance type
Public
Private
Living environment
Home
LTAC/rehabilitation/nursing home
Homeless
Unknown
County poverty, 20%*
History of SUD treatment†
Stigmatizing language in EMR
ID consultation
Appropriate antimicrobial therapy
Presence of withdrawal signs/symptoms
Outcomes
Primary
Completed antimicrobial course of therapy
Unplanned discharge
30-D readmission
Mortality
Adverse events‡
Length of stay

Total Population
(N = 119)
39 (32–51.5)
73 (61.3)
72 (60.5)
1 (0.8)

SUD Resources
Implemented (n = 74)
36.5 (30–50.3)
45 (60.8)
43 (58.1)
1 (1.4)

SUD Resources Not
Implemented (n = 45)
41 (33–58)
28 (62.2)

P
0.076
0.878
0.615

29 (64.4)
0 (0)
0.422

24 (20.2)
90 (75.6)
5 (4.2)
24 (21.7–27.8)
1 (0–2)
5 (4.2)
73 (61.3)
119 (100)

12 (16.2)
59 (79.7)
3 (4.1)
23.4 (21.7–27.3)
1 (0–2)
4 (5.4)
42 (56.8)
74 (100)

12 (26.7)
31 (68.9)
2 (4.4)
25.1 (21.2–28.2)
1 (0.5–3)
1 (2.2)
31 (68.9)
45 (100)

0.166
0.099
0.649
0.188
—
0.162

74 (62.2)
4 (3.4)
3 (2.5)
2 (1.7)
36 (30.3)

49 (66.2)
1 (1.4)
1 (1.4)
2 (2.7)
21 (28.4)

25 (55.6)
3 (6.7)
2 (4.4)
0 (0)
15 (33.3)

11 (9.2)
29 (24.4)
15 (12.6)
1 (0.8)
2 (1.7)
61 (51.3)
117 (98.3)

5 (6.8)
22 (29.7)
11 (14.9)
0 (0)
1 (1.4)
35 (45.9)
73 (98.6)

6 (13.3)
7 (15.6)
4 (8.9)
1 (2.2)
1 (2.2)
26 (57.8)
44 (97.8)

106 (89.1)
11 (9.2)

65 (87.8)
8 (10.8)

41 (91.1)
3 (6.7)

104 (87.4)
3 (2.5)
10 (8.4)
2 (1.7)
59 (49.6)
75 (63)
117 (98.3)
82 (68.9)
111 (93.3)
53 (44.5)

63 (85.1)
3 (4.1)
7 (9.5)
1 (1.4)
34 (45.9)
56 (75.7)
73 (98.6)
56 (75.7)
67 (90.5)
38 (51.4)

41 (91.1)
0 (0)
3 (6.7)
1 (2.2)
25 (55.6)
19 (42.2)
44 (97.8)
26 (57.8)
44 (97.8)
15 (33.3)

0.309
<0.001
1.000
0.060
0.256
0.055

43 (58.1)
55 (74.3)
22 (29.7)
13 (17.6)
0 (0)
1 (1.4)
7 (4–13.3)

19 (42.2)
24 (53.3)
18 (40)
10 (22.2)
2 (4.4)
0 (0)
4 (2–6.5)

0.093
0.019
0.250
0.533
0.141
1.000
<0.001

0.205

1.000
0.532
0.532

62 (52.1)
79 (66.4)
40 (33.6)
23 (19.3)
2 (1.7)
1 (0.8)
5 (3–10)

*County poverty was defined using the US Census Bureau data.
†Substance use disorder treatment history was considered history of MOUDs or history of treatment/admission to an addiction medicine facility.
‡Adverse events: line complications, allergic reactions, antimicrobial associated hematologic abnormalities, vancomycin infusion reactions, antimicrobial associated electrolyte abnormalities, and Clostridioides difficile infections.
BMI, body mass index; CCI, Charlson Comorbidity Index; GED, general education development; LTAC, long-term acute care; HCV, hepatitis C virus; ID, infectious disease.
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TABLE 2. Univariate and Multivariable Logistic Regression Model Predictors of Primary Outcome
Characteristic

Primary Outcome Success

Primary Outcome Failure

OR (95% CI)

aOR (95% CI)

43 (58.1)
6 (30)
4 (33.3)
19 (67.9)

31 (41.9)
14 (70)
8 (66.7)
9 (32.1)

0.727 (0.491–1.076)
1.886 (0.944–3.764)
1.626 (0.717–3.688)
0.696 (0.498–0.973)

2.593 (1.162–5.789)
0.232 (0.078–0.692)
0.428 (0.115–1.591)
1.699 (0.660–4.371)

Inpatient SUD therapy implemented
Infective endocarditis
Bone and joint infections
Pneumonia
*Hosmer-Lemeshow test = 0.899.
aOR, adjusted OR.

0.05 were considered significant. Statistical analysis was performed using IBM SPSS Statistics version 25 (Armonk, NY).

RESULTS
The study included 119 patients: 74 (62.2%) had SUD resources implemented, composed of 13 addiction medicine consults
(17.6%), 61 behavioral health consults (82.4%), 3 opioid withdrawal protocols (4.1%), 10 methadone continuations (13.5%),
and 30 buprenorphine initiations (40.5%). Baseline characteristics are in Table 1. The patients who received SUD resources
during their inpatient admission were more likely to have previously received SUD treatment (75.7 vs 42.2, P < 0.001). Stigmatizing language was present in 98% of EMRs.
The most common infection types were skin and soft tissue
infections—SSTI (54.6%), endovascular (28.6%), and pneumonia (23.5%). The patients with endocarditis were more likely to
have received SUD resources (24.3 vs 4.4, P = 0.005). SSTIs
were more prevalent in those without resources (64.4 vs 48.6,
P = 0.093). Methicillin-resistant Staphylococcus aureus was the
most common organism (26), followed by Streptococcus species
(22) and methicillin-sensitive S. aureus (17).
Opioid therapy was prescribed for inpatient use in 54 patients (73%) also receiving inpatient SUD resources and 36 patients without resources (80%, P = 0.387). Alternative SUD
medications (anticholinergics, antipsychotics, anxiolytics, benzodiazepines) were used in 46 patients with SUD resources
(62.2%) and 34 without (75.6%, P = 0.131). Buprenorphine
was offered to 41 patients, with 30 (73.2%) initiating therapy.
Discharge SUD resources occurred in 29 patients with inpatient
resources (39.2%) and 4 without (8.9%, P < 0.001). Take-home
naloxone was prescribed in 11 (14.9%) and 3 (6.7%) patients
who did and did not receive inpatient resources ( P = 0.178), respectively. Outpatient buprenorphine was prescribed in 14 patients (18.9%) who received inpatient resources and 1 (2.2%)
who did not ( P = 0.008). Follow-up visits were only scheduled
in the patients who received SUD resources (8 vs 0, P = 0.022),
with 6 visits attended. Admissions to inpatient addiction treatment facilities occurred in 8 patients.
Patient outcomes are displayed in Table 1. The composite
outcome was met by 43 patients with SUD resources (58.1%)
and 19 patients without (42.2%, P = 0.093). After adjustment
for infection type, implementation of inpatient resources (adjusted OR, 2.593; 95% CI, 1.162–5.789) was independently associated with primary outcome success (Table 2).

DISCUSSION
Patients with implementation of SUD resources during
hospitalization were 2.6 times more likely to have a successful
© 2022 American Society of Addiction Medicine

infection outcome. Resourced patients had more completions
of antibiotic therapy (74.3 vs 53.3, P = 0.019) and fewer unplanned discharges (29.7 vs 40, P = 0.250). Previous literature
suggests a 5.6 times likelihood of success for antimicrobial therapy completion and 51% to 80% reduction in unplanned discharges with addiction medicine consultation and MOUDs.9,10
This study also supports other literature highlighting the importance of interdisciplinary collaboration of infectious diseases
and addiction medicine providers.
Missed opportunities are evident. Inpatient resources are
not being fully used with 38% of patients lacking available resources. In addition, only 24% of patients were discharged with
outpatient resources. In 2019, lack of naloxone prescribing was
highlighted, placing persons with SUD as a target population.12
Barriers to SUD resource implementation at discharge include
education, time/training, and concern for risky behavior. 12,13
Lastly, 98% of EMRs contained stigmatizing language, highlighting the need for education on stigmatizing language and
implicit bias.11,14,15
This study has several strengths. Patient characteristics
were assessed for relationships with the decision to implement/
not implement SUD resources. Persons who inject stimulants
and/or opioids were of focus due to challenges in optimizing infectious diseases management. In addition, findings are consistent with current literature, further establishing the necessity of
improving SUD management.
The limitations of this study are notable. Human and programming error may exist with ICD-10 codes collected via automatic query and manually extracted covariates. The patients
also were unable to be categorized by type of drug injected because of inconsistent EMR documentation. Furthermore, multiple strategies were deployed to minimize bias. Selection bias
was minimized by screening all SUD ICD-10 codes. To minimize information bias, evaluation of objective information and
the sexual orientation and gender identity form within the
EMR was performed. Many variables, however, relied on accurate self-reporting/documentation. Subjective data presented in
areas such as withdrawal signs/symptoms. Confounding variables were minimized by regression and collection of characteristics that could predispose patients to variations in care (sexual
orientation, gender identity, etc).

CONCLUSIONS
Care to PWIDs with infections is optimized when SUD
resources are implemented. After adjusting for infection type,
patients with resources were 2.6 times more likely to complete
antimicrobial therapy, experience a planned discharge, and not
be readmitted within 30 days. This study further contributes to
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evidence supporting implementation of inpatient SUD resources
for PWIDs.
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